umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Lipoprotein lipase is differentially expressed in prognostic subsets of chronic lymphocytic leukemia but displays invariably low catalytical activity
Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Umeå University, Faculty of Medicine, Department of Medical Biosciences, Physiological chemistry.
Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Show others and affiliations
2010 (English)In: Leukemia research, ISSN 1873-5835, Vol. 34, no 3, 301-306 p.Article in journal (Refereed) Published
Abstract [en]

Lipoprotein lipase (LPL) expression has been shown to correlate with IGHV mutational status and to predict outcome in chronic lymphocytic leukemia (CLL). We here investigated the prognostic impact of LPL expression in relation to other prognostic markers including IGHV3-21 usage in 140 CLL patients. Additionally, we studied the catalytic activity of LPL in CLL cells. A significant difference in LPL mRNA expression was detected in IGHV unmutated compared to mutated CLL patients (p<0.001). However, the poor-prognostic mutated/stereotyped IGHV3-21 patients did not differ from other mutated CLL cases. Clinical outcome was significantly different in CLL cases with high versus low LPL expression (p<0.001), and LPL expression exceeded mutation status/IGHV3-21 usage as an independent prognostic marker. Finally, LPL protein expression correlated significantly with mRNA expression and was higher in IGHV unmutated versus mutated CLL (p=0.018), although the majority of synthesized protein was catalytically inactive indicating a non-catalytical function in CLL.

Place, publisher, year, edition, pages
Elsevier, 2010. Vol. 34, no 3, 301-306 p.
Keyword [en]
LPL expression, LPL catalytical activity, IGHV mutational status, IGHV3-21 usage, Chronic lymphocytic leukemia, Prognosis
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:umu:diva-30374DOI: 10.1016/j.leukres.2009.07.032ISI: 000274529600008PubMedID: 19709746OAI: oai:DiVA.org:umu-30374DiVA: diva2:282362
Available from: 2009-12-19 Created: 2009-12-19 Last updated: 2012-02-13Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Authority records BETA

Roos, GöranOlivecrona, Gunilla

Search in DiVA

By author/editor
Roos, GöranOlivecrona, Gunilla
By organisation
Physiological chemistryPathology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 79 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf